Ghazi Lama, Chen Xinyuan, Harhay Michael O, Hu Liangyuan, Biswas Aditya, Peixoto Aldo J, Li Fan, Wilson F Perry
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama.
Department of Mathematics and Statistics, Mississippi State University, Mississippi State, Mississippi.
Am J Kidney Dis. 2025 Apr;85(4):442-453. doi: 10.1053/j.ajkd.2024.09.011. Epub 2024 Nov 22.
RATIONALE & OBJECTIVE: Severe hypertension (HTN) that develops after hospital admission is prevalent in 10% of patients admitted for reasons other than HTN. Severe HTN is commonly treated with intravenous (IV) antihypertensives and is associated with a greater risk of acute kidney injury (AKI). We explored whether there is heterogeneity in IV antihypertensives' effect on AKI incidence among patients who develop severe HTN during hospitalization.
Heterogeneity of treatment effect analysis.
SETTINGS & PARTICIPANTS: Patients who developed severe HTN, defined as systolic blood pressure (BP)>180 or diastolic BP>110mm Hg, during hospitalization and did not have kidney failure.
Treatment with IV antihypertensives within 3 hours of BP elevation.
Time to developing AKI.
An accelerated failure time Bayesian additive regression trees (BART) model to capture the association between the time to develop AKI and predictors. Individual treatment effects were estimated for each participant using a counterfactual outcome framework, and these estimates were used to identify patient characteristics associated with treatment effect heterogeneity in response to IV antihypertensives.
We included 11,951 patients who developed severe HTN, 741 were treated with IV antihypertensives, and 11,210 were not, of whom 18% and 13% developed AKI, respectively. Most patients would have been harmed from IV antihypertensive treatment except for a small subset of 317 patients who were White, had a systolic BP on admission≥156mm Hg, an estimated glomerular filtration rate of≥70.7mL/min/1.73m, and a serum bicarbonate of<21.7mmol/L.
Data-driven, hypothesis-generating approach. Findings were not validated with external data sources.
These exploratory findings suggest that most patients who develop severe HTN will not benefit from IV antihypertensive treatment. Future studies should assess for heterogeneity when identifying treatment options, if any are needed, for severe HTN.
PLAIN-LANGUAGE SUMMARY: Patients who develop severe blood pressure elevation during hospitalization are commonly treated with intravenous antihypertensives; however, this could lead to acute kidney injury (AKI). We wanted to assess whether this is consistent across all patients, using a new statistical approach that predicts what would happen if patients who were treated had not been treated and those who were not treated had been. We found that most patients will develop AKI, and only a small subset of patients might not. This exploratory study can help inform future studies on the treatment of hypertension that develops during hospitalization.
因非高血压原因入院的患者中,有10%会在入院后出现重度高血压(HTN)。重度高血压通常采用静脉注射(IV)抗高血压药物治疗,且与急性肾损伤(AKI)风险增加相关。我们探讨了在住院期间发生重度高血压的患者中,静脉注射抗高血压药物对AKI发生率的影响是否存在异质性。
治疗效果异质性分析。
在住院期间发生重度高血压(定义为收缩压(BP)>180或舒张压BP>110mmHg)且无肾衰竭的患者。
血压升高后3小时内使用静脉注射抗高血压药物治疗。
发生AKI的时间。
采用加速失效时间贝叶斯加法回归树(BART)模型来捕捉发生AKI的时间与预测因素之间的关联。使用反事实结果框架为每位参与者估计个体治疗效果,并将这些估计值用于识别与静脉注射抗高血压药物治疗效果异质性相关的患者特征。
我们纳入了11951例发生重度高血压的患者,其中741例接受了静脉注射抗高血压药物治疗,11210例未接受治疗,接受治疗和未接受治疗的患者中分别有18%和13%发生了AKI。除了一小部分317例患者外,大多数患者接受静脉注射抗高血压药物治疗可能会受到伤害,这部分患者为白人,入院时收缩压≥156mmHg,估计肾小球滤过率≥70.7mL/min/1.73m²,血清碳酸氢盐<21.7mmol/L。
数据驱动的假设生成方法。研究结果未用外部数据源进行验证。
这些探索性研究结果表明,大多数发生重度高血压的患者不会从静脉注射抗高血压药物治疗中获益。未来的研究在确定重度高血压的治疗方案(如果需要的话)时,应评估是否存在异质性。
在住院期间出现严重血压升高的患者通常采用静脉注射抗高血压药物治疗;然而,这可能会导致急性肾损伤(AKI)。我们想评估这在所有患者中是否一致,采用一种新的统计方法来预测如果接受治疗的患者未接受治疗以及未接受治疗的患者接受治疗会发生什么。我们发现大多数患者会发生AKI,只有一小部分患者可能不会。这项探索性研究有助于为未来关于住院期间发生的高血压治疗的研究提供信息。